Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15504853 | 1.00 | CYP1A2 (0.68) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL12611837 | 0.81 | CYP1A2 (0.46) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL15514079 | 0.81 | CYP1A2 (0.46) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL15514385 | 0.81 | LMNA (0.66) | LMNAALDH1A1MAPTKMT2ARAB9A | |
| SCHEMBL15504854 | 0.81 | LMNA (0.66) | LMNAALDH1A1MAPTKMT2ARAB9A | |
| SCHEMBL9231501 | 0.81 | RAB9A (0.74) | ALDH1A1MAPTKDM4EHTTKMT2A | |
| SCHEMBL15514419 | 0.81 | TDP1 (0.60) | LMNAALDH1A1MAPTKDM4EHTT | |
| SCHEMBL15504851 | 0.81 | TDP1 (0.60) | LMNAALDH1A1MAPTKDM4EHTT | |
| SCHEMBL12612180 | 0.75 | ADORA3 (0.50) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL15513845 | 0.75 | ADORA3 (0.50) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662180-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20180215742-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-08-02 | — | — | US | disclosed |
| US-9878999-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20140073650-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662180-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | PSMB3, PSME3, PSMD3 | CYP1A2 2569/4885CYP3A4 1630/4885CYP2D6 2717/4885 |
| US-20140073650-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | PSMB3, PSME3, PSMD3 | CYP1A2 2569/4885CYP3A4 1630/4885CYP2D6 2717/4885 |
| US-20180215742-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | PSMB3, PSME3, PSMD3 | CYP1A2 2569/4885CYP3A4 1630/4885CYP2D6 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.